Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 30;13(19):4951. doi: 10.3390/cancers13194951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Time to third treatment (TTTTD) and overall survival (OS) comparisons between alternate novel hormonal therapy and docetaxel in patients treated with (a) first-line abiraterone (Figure 7a) and (b) first line-enzalutamide (Figure 7b).

Time to third treatment (TTTTD) and overall survival (OS) comparisons between alternate novel hormonal therapy and docetaxel in patients treated with (a) first-line abiraterone (Figure 7a) and (b) first line-enzalutamide (Figure 7b).